scispace - formally typeset
S

Sagar Lonial

Researcher at Emory University

Publications -  775
Citations -  58107

Sagar Lonial is an academic researcher from Emory University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 89, co-authored 712 publications receiving 48332 citations. Previous affiliations of Sagar Lonial include Cincinnati Children's Hospital Medical Center & Emory University Hospital.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy

Daniel J. Klionsky, +1287 more
- 01 Apr 2012 - 
TL;DR: These guidelines are presented for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

TL;DR: The disease definition of multiple myeloma is updated to include validated biomarkers in addition to existing requirements of attributable CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions), and specific metrics that new biomarkers should meet for inclusion in the disease definition are provided.
Journal ArticleDOI

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

TL;DR: Several aspects of disease response assessment are clarified, along with endpoints for clinical trials, and future directions for disease response assessments are highlighted, to allow uniform reporting within and outside clinical trials.